The Cancer Targeting Gene-Viro-Therapy (CTGVT) is constructed by inserting an antitumor gene into an oncolytic virus vector (OV), it is actually a strategy of OV-gene therapy.The CTGVT (OV-gene) has much higher antitumor effect than that of either gene therapy alone or oncolytic virotherapy alone because that OV can target to cancer cell and replicate in it several hundred folds and the inserted gene can also replicate several hundred folds, therefore the antitumor effect CTGVT (OV-gene) will be much increased.However the CTGVT is only a basis for super antitumor therapy, many modifications have been made by us for its antitumor studying.For example, by the combined use of two CTGVT i.e., the OV-gene 1 plus OV-gene2, it wad called as Cancer Targeting of Dual Gene-Viro-Therapy (briefly CTGVT-DG), all the xenograft tumors could be completely eliminated if two suitable genes were chosen.The tissue specific cancer therapy has also been constructed, for example, the liver cancer suppressor gene HCCS 1 or SOCS3 to be drived by liver cancer specific promoter AFP, such as Ad.AFP.E1A.E1B(△ 55)-HCCS 1, it was called as CTGVTLC.Professor Liu was the earliest one to combine gene therapy and virotherapy together and was the first one to name it as a strategy of CTGVT.The CTGVT has been studied persistently by us for more than 10 years and more than 70 peer reviewed papers have been published by our lab.Now it has been become a hot topic to be studied worldwide.Amgen paid 1 billion USD to purchase the OncoHSV-GM-CSF (OV from Herpes Simple Virus) from BioVex.An OncoPox-GM-CSF from Jennerex was published in Nature.We will publish our paper concerning OncoPoxgene which will be sure with higher antitumor effect than that of the OncoPox-GM-CSF in the Nature paper.